In 2018, the randomized placebo-controlled, double-blind tafamidis in transthyretin amyloid cardiomyopathy clinical trial (ATTR-ACT) demonstrated that tafamidis was effective in treating patients with ATTR-CM with NYHA functional class I to III [78]. This evidence concerns the gene TTR and cardiac amyloidosis.